Literature DB >> 16250844

RNA interference-based gene silencing in mice: the development of a novel therapeutical strategy.

Birgit Spänkuch1, Klaus Strebhardt.   

Abstract

RNAi (RNA interference) was originally detected in Caenorhabditis elegans as biological response to exogenous double-stranded RNA (dsRNA), which induces very effective sequence-specific silencing of gene expression. Further investigations revealed that RNAi can occur in many eukaryotic species. Increasing understanding of the biochemical components of RNAi indicates the existence of a conserved machinery for dsRNA-induced gene silencing that acts in two steps. In the first step, an RNase III family nuclease called Dicer processes the dsRNA to small interfering RNAs (siRNAs) 21-23 nt in length. These siRNAs enter a multimeric nuclease complex that identifies target mRNAs through their homology to siRNAs and induce destruction of the corresponding mRNAs. Since RNAi has become an excellent strategy for gene silencing, it is tempting to apply this technology to 'knock-down' gene expression in living animals. The generation of transgenic mice from embryonic stem cells expressing small hairpin RNAs (shRNAs) has provided evidence for in vivo application of RNAi. Furthermore, different experimental strategies have been developed to analyze the influence of chemically synthesized siRNAs and of vector-based shRNAs on the expression of different transgenes and endogenous genes in vivo. Recent studies describe the in vivo delivery of siRNAs to inhibit transgene expression in certain organs of adult mice, predominately murine liver. Strategies for the inhibition of cellular proliferation by systemic treatment of tumor-bearing animals with siRNAs are beginning to emerge. They are of utmost interest for systemic diseases such as cancer. In addition, several groups have shown that RNAi can also be used to block the infectivity or suppress the replication of different RNA viruses relevant to human diseases including human immunodeficiency virus-1 (HIV-1) and hepatitis C virus (HCV). In summary, multiple lines of evidence indicate that RNAi seems to become a powerful tool for the fight against undesirable gene expression in human diseases.

Entities:  

Mesh:

Year:  2005        PMID: 16250844     DOI: 10.2174/138161205774370834

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  5 in total

Review 1.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

2.  Hepatic stellate cell-specific gene silencing induced by an artificial microRNA for antifibrosis in vitro.

Authors:  Ying Chang; Hua-jun Jiang; Xue-mei Sun; Xiao-kun Cai; Xing-xing He; Pei-yuan Li; Wang-xian Tang; Yu-hu Song; Ju-sheng Lin
Journal:  Dig Dis Sci       Date:  2009-11-05       Impact factor: 3.199

3.  Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice.

Authors:  Hongxia Zhou; Björn H Falkenburger; Jörg B Schulz; Kim Tieu; Zuoshang Xu; Xu Gang Xia
Journal:  Int J Biol Sci       Date:  2007-03-05       Impact factor: 6.580

4.  Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits the growth and invasion of hepatocellular carcinoma via down-regulating midkine expression.

Authors:  Cai Qun Bie; Xu You Liu; Ming Rong Cao; Qiu Yan Huang; Hui Jun Tang; Min Wang; Guo Li Cao; Ting Zhuang Yi; Sheng Lan Wu; Wei Jie Xu; Shao Hui Tang
Journal:  Oncotarget       Date:  2016-11-29

5.  Lentivirus-mediated siRNA knockdown of SPHK1 inhibits proliferation and tumorigenesis of neuroblastoma.

Authors:  Lin Su; Junyan Tian; Jinsong Sun; Nuan Han; Lin Feng; Baohua Yu; Yuepeng Wang
Journal:  Onco Targets Ther       Date:  2018-10-18       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.